# Astellas to build ¥10B API manufacturing facility for Prograf in Toyama, Japan

Astellas Pharma announced the construction of a new manufacturing facility for the active pharmaceutical ingredient of Prograf at its Toyama Technology Center in Japan. The total construction cost is approximately ¥10.0 billion, with construction starting in April 2020 and completion scheduled for August 2021.

- Type: Expansion
- Announced: 2020-01-17
- Where: Toyama, Japan
- Value: $92.0M (10.0B JPY)
- Starts operating: Aug 2021
- Status: announced
- Capacity: 7220 m2 total floor area
- Products: active pharmaceutical ingredient of Prograf (tacrolimus hydrate)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Astellas Pharma Inc.](https://endata.com/companies/35227.md)
- [Astellas Pharma Tech](https://endata.com/companies/44607.md) (partner)

## Sources

- [newsroom.astellas.com](https://newsroom.astellas.com/2020-01-17-Astellas-Announces-Construction-of-New-Manufacturing-Facility-for-Active-Pharmaceutical-Ingredient-of-Prograf-R-in-Toyama-Technology-Center), 2020-01-17: "The purpose of the construction of the Third Fermentation Building is to enhance our production capacity that will enable a stable supply of high-quality products in the future."
- [pharmafocusasia.com](https://www.pharmafocusasia.com/projects/astellas-to-construct-new-pharma-manufacturing-facility-in-japan), 2020-02-28: "Astellas Pharma has announced its plans to construct a new pharma manufacturing facility at an investment of around US$91 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.